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Abstract
Objective—Numerous studies have discussed the value of including biological outcome measures
as a complement to behavioral outcome measures to assess the efficacy of HIV risk-reduction
interventions. This article highlights strategies used to minimize the limitations of including both
self-reported sexual behaviors and biologically confirmed sexually transmitted diseases as primary
outcome measures in an HIV/sexually transmitted disease (STD) prevention program for African
American serodiscordant couples (EBAN).
Design—Couples receiving an HIV intervention condition (EBAN) were compared with couples
receiving a time-equivalent General Health Promotion condition on behavioral and biological
outcomes. Both behavioral and biological data were collected at baseline, immediately
postintervention, and at 6 and 12 months postintervention.
Methods—Literature reviews, consulting other researchers who conducted couples studies, our
investigative team’s experience in previous HIV interventions, and formative work were used to
develop procedures to minimize potential limitations associated with the inclusion of behavioral and
biological outcome measures for EBAN.
Results—Given the strengths of including behavioral and biological outcome measures, the EBAN
study chose to have both measures serve as primary outcomes. The primary behavioral outcome for
the trial is the proportion of protected vaginal and anal intercourse episodes that occurred within the
index couple in 90 days before each follow-up assessment and over the 12-month postintervention
follow-up period. The primary biological outcome is the proportion of participants (male or female
study partners) with an incident STD (chlamydia, gonorrhea, or trichomoniasis) over the 12-month
postintervention follow-up period.
Conclusions—Employing procedures to minimize limitations of using self-reported sexual
behaviors and STDs as complementary primary outcomes enhances their utility as measures of the
efficacy of HIV/STD prevention interventions.
INTRODUCTION
People living with HIV are now living longer and more sexually active lives.1 Many individuals
who test positive for HIV reduce or eliminate behaviors that can transmit HIV to others.2,3
However, these reductions are not absolute because individuals who reduce HIV risk behaviors
may not maintain these practices for a lifetime. Several studies have demonstrated that
approximately one-third of persons diagnosed with HIV infection may continue to engage in
sexual practices.4 These behaviors place their HIV-negative sexual partners at risk of disease
acquisition and themselves and other HIV-positive sexual partners at risk for exposure to
infection with a different strain of HIV. Decreasing the number of unprotected sexual acts
between individuals living with HIV and persons of unknown or HIV-negative status is the
most targeted method of reducing sexual transmission of HIV.5 Therefore, evaluating the
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impact of a behavioral intervention for HIV-serodiscordant couples requires measuring sexual
risk behaviors targeted by the intervention.
Historically, HIV prevention interventions have relied almost exclusively on individuals’ self-
reported behavior change to assess intervention efficacy.6 Typical self-reported behaviors that
have served as the cornerstone of assessing intervention efficacy include frequency of condom
use, number of different sexual partners, or frequency of drug use when engaging in sexual
behavior.6 EBAN trial investigators believe that using a measure of self-reported sexual
behavior is crucial because it is the most frequently used behavioral outcome in HIV prevention
trials. Additionally, the study assessed a set of theoretically derived mediating variables
through which change in self-reported risky sexual behaviors is hypothesized to occur.
However, for numerous reasons, trial investigators were cautious about relying entirely on the
measurement of self-reported sexual behaviors to assess programmatic efficacy. First, several
observational studies exploring the relationship between behavioral and biomedical outcomes
have failed to show a strong relationship between individuals’ risk behaviors and sexually
transmitted disease (STD) acquisition.7 Additionally, some HIV interventions have not
observed a strong relationship between individuals’ sexual behaviors and STD acquisition.8
Furthermore, there is ample empirical evidence suggesting that self-report of sexual behavior
may be subject to potential reporting biases, such as inaccurate recall bias (encoding, distortion,
retrieval, and reconstruction)9–11 and social desirability bias.12,13
Over the past several decades, improvements in the formatting and framing of sexual behavior
questions have enhanced the validity of self-reported sexual behaviors. Research shows that
estimates of sexual behavior are more likely to be valid if surveys enquire about behaviors that
occur during shorter recall periods.11,13 Use of cues, such as activities and important events,
have also been beneficial.9,14,15 Additionally, the advent of audio computer-assisted self-
interviewing (ACASI) has reduced barriers to literacy, minimized social desirability bias, and
has been shown to yield higher rates of self-reported sexual behaviors than interviewer-
administered or self-administered surveys.13,16 Even with these advances, assessment of
sexually transmitted infections (STIs) has been advocated as a complementary measure for
evaluating programmatic efficacy.17,18
Historically, the primary drawback of using biological markers, such as STDs, was the logistics
of data collection. Data collection was typically feasible only in a clinical environment, such
as a doctor’s office or an STD treatment center, and often required trained clinicians utilizing
invasive procedures. Recently, however, major developments have been made in STD
diagnostic procedures, in particular the introduction of DNA amplification assays that have
high sensitivity and specificity. With the availability of these DNA amplification techniques
that can identify bacterial STDs in urine specimens, in particular prevalent STDs such as
chlamydia and gonorrhea, it is now possible to detect STDs in a noninvasive manner in a broad
range of nonclinical settings.19–24 The development of this diagnostic technology paved the
way for greater utilization of STDs as a clinical end point in evaluating HIV prevention
interventions.
Furthermore, including STIs as an end point in HIV prevention trials recognizes the impact of
STD on HIV transmission. Specifically, HIV-positive persons with an STD may be more likely
to transmit HIV to others due to the effects of the STD on HIV infectivity, such as increased
shedding of HIV. Furthermore, HIV-negative persons with an STD may be more susceptible
to a subsequent exposure to HIV because the STD may compromise the mucosal or cutaneous
surfaces of the genital tract that normally act as a barrier against HIV.25
The use of biological end points, while representing an objective and quantifiable marker of
high-risk sexual behavior, is not without controversy nor is it a panacea for avoiding bias
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associated with self-report. It is important to recognize that reliance on incident STDs as a
measure of program efficacy may not be an appropriate outcome for every study. It is unlikely,
for instance, that the incidence of STDs will be changed in a short-term study conducted in a
population with little sexual activity or in a community with a low prevalence of STDs.26
Conversely, populations with a high degree of sexual activity and a high prevalence of STDs
are ideal for studying the effects of behavioral interventions on STD incidence. Moreover,
studies incorporating biological markers as the primary outcome measure need to be conducted
with samples that are sufficiently large and a follow-up of sufficient duration to provide
adequate statistical power to detect differences in STD incidence.26
A review of randomized controlled trials of individual-level, population-level, and multilevel
interventions for preventing STIs identified 41 trials that met inclusion criteria and used STD
outcomes as objective measures of intervention efficacy.27 Among individual- and group-level
interventions, 32 targeted acquisition, 4 targeted transmission, and 1 targeted complications of
STIs. The most common intervention modality used was behavioral interventions; 11 of the
41 of the interventions were designed to reduce high-risk sexual practices. Notably, few of the
studies in this review have been conducted among HIV-positive individuals.27 One trial was
efficacious in reducing STDs among individuals living with HIV28 and another trial reported
a reduction in STD symptoms in couples.29 There have not been any published HIV prevention
trials conducted among African American serodiscordant couples using biological outcome
markers as measures of efficacy. The EBAN trial investigators sought to use a primary
biological outcome measure to complement the use of a behavioral outcome measure to assess
intervention efficacy given the moderate degree of risky sexual behaviors,4 and STDs,30
among individuals living with HIV; the experience of the EBAN trial investigators in using
STDs to assess HIV intervention efficacy28,31; the 12-month follow-up period to assess
incident STD acquisition; the large study sample of African American couples (N = 536
couples); and the public health significance of reducing STD acquisition among African
American HIV-serodiscordant couples.32
This article describes approaches used to minimize limitations in using self-reported sexual
behavior and objective STD data as primary outcomes in an HIV/STD prevention program for
African American serodiscordant couples (EBAN).
Data Collection
In this 2-armed randomized controlled trial, data collection for the primary behavioral outcome
and the primary biological outcome was generated from 3 data sources over 4 assessment
points. Specifically, data were collected from participants at the baseline, the immediate
postintervention assessment, and the 6- and 12-month follow-up assessments. Urine and
vaginal swabs were used to identify 3 STDs. ACASI was administered to assess the primary
behavioral outcome, and the administration of ACASI in this trial is discussed in greater detail
in the article Designing an Audio Computer Assisted Self Interview (ACASI) System in a
Multisite Trial: A Brief Report. Table 1 provides a description of the data collection modalities
used in this trial.
DEFINING THE PRIMARY BEHAVIORAL OUTCOME
A number of indices are typically used as the primary behavioral outcome; however, proportion
of protected intercourse episodes is one of the most commonly used measures to assess outcome
efficacy in HIV prevention trials. Therefore, to facilitate comparability to other studies of HIV
prevention, this definition of the primary behavioral outcome was adopted in this trial.
Specifically, the primary behavioral outcome is defined as “the proportion of vaginal and anal
intercourse episodes that occurred within the index couple that were protected in the past 90
days and over the 12-month postintervention follow-up period. Protection is defined as the
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number of times that either a male condom or a female condom was used by the index couple
divided by the number of times the index couple had vaginal or anal sex in the prior 90 days
and over the 12-month postintervention follow-up period.”
Enhancing the Validity and Reliability of Self-Reported Sexual Behavior Data in Couples
Given the trial’s primary behavioral outcome, couples’ self-reports of sexual behavior must be
assessed. In using self-report measures, there are 2 psychometric properties that are important:
(1) reliability—which indicates that the results are consistent and not random—and (2) validity
—which indicates that the investigator and the respondent understand the meaning of the
question in the same way. Findings from several studies indicate that there is a fair to good
concordance for whether a couple has ever used a condom among HIV-discordant couples.
31,32 Reports of less frequently occurring behaviors (eg, oral sex) within a couple are less
consistently recalled.32 The validity and reliability of sexual behavior in couples’ sexual
behavior may be influenced by many variables, including (1) the cultural and gender mores of
the social group to which the couple belongs, (2) the manner in which information on sexual
behavior is obtained, (3) the level of social desirability bias, (4) the couple’s memory or recall
of their sexual practices, and (5) the prevalence of condom-use errors. The trial sought to
address each of these 5 challenges to enhance the validity and reliability of the primary
behavioral outcome measure.
Emphasizing Cultural Congruence and Gender Sensitivity in the Assessment Procedures
Unfortunately, the legacy of failing to provide informed consent with African Americans has
had negative ramifications for many African Americans involved in research studies.35 To
enhance the willingness of couples to provide valid and reliable information about their sexual
behavior, participants were assured of the confidentiality of their data as part of the informed
consent. After providing informed consent, a male research assistant escorted all male study
participants to a private room in which the ACASI, beverages, and African American art or
other ethnic crafts were displayed. Likewise, an African American female research assistant
escorted all female study participants to a separate private room that contained similar materials
present in the room for men. The aim of these procedures was to create a culturally attractive
and comfortable setting for participants. Additionally, the trial investigators sought to enhance
participants’ confidence in the researchers and study staff’s gender sensitivity and cultural
competency.
Administering ACASI
The advent of ACASI has reduced barriers to literacy, minimized social desirability bias, and
has been shown to yield higher rates of reporting risky sexual behaviors than interviewer-
administered or self-administered surveys.13,16 However, ACASI had not previously been
used with African American couples. Therefore, before implementing the trial we piloted the
ACASI with 32 couples to assess the feasibility and reliability of using ACASI to administer
the study interview (see article on ACASI as part of this issue). Additionally, to enhance the
reliability and validity of self-reported sexual behaviors the EBAN trial used the following
procedures: (1) defined the terms vaginal, anal, and oral sex, so participants would not have to
translate the meaning of these more technical terms into more commonly used nomenclature
for sexual practices, (2) clarified what was meant by the number of times a person has sex (if
a person had sex more than one time in a given day we would count each time they had sex as
an episode), (3) added the word “about” when asking participants how many times they
engaged in specific sexual behavior to reduce extrapolating to thinking about every episode of
sex, (4) added a pop-up screen on the ACASI that indicated the number of times a person has
sex, (5) programmed the ACASI so that it would not proceed if the number of times a participant
used condoms is greater than the number of times they reported sex, (6) provided clear
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instructions informing participants that the time frame for reporting their sexual behaviors
changed, (7) used instruments that have established reliability and validity with African
Americans, and (8) whenever possible, used complete scales rather than partial measures to
assess a study construct.
Minimizing Social Desirability Bias
To minimize socially desirable responses, a motivational statement at the introduction of the
ACASI sexual behavior section appealed to participants’ sense of altruism and indicated that
the results of this study would be important for the African American community. Additionally,
a social desirability scale36 was embedded in the ACASI to assess social desirability tendency.
Finally, the training of assessment staff discussed methods for enhancing validity of self-
reported sexual behaviors, and staff were trained to be warm and nonjudgmental toward study
participants and to encourage candid responding.
Enhancing Recall
Couples’ self-reported sexual practices may be inaccurate because of lack of recall.37
Responses may unintentionally be inaccurate due to the difficulty of remembering when
particular behaviors occurred. Increased bias of sexual behavior has been attributed to longer
periods of recall between the interview and the sexual activity under question.38 Very recent
recall periods (ie, in the past 2 weeks or the past month) allow for less recall bias but may not
capture infrequent sexual events. Therefore, to enhance recall of our primary behavioral
outcome and other sexual behaviors assessed, the EBAN trial (1) used the Timeline Followback
method, which incorporates the use of recall-enhancing techniques, such as calendars for a
specific recall period (90-day calendar), to provide visual cues to aid in retrospective recall of
sexual behaviors13; (2) assessed sexual behaviors at 4 time periods (past 90 days, past 30 days,
typical week, and at last sexual intercourse); and (3) provided the dates corresponding to the
90-day and 30-day recall interval on the ACASI screen.13,37
Assessing Condom-Use Errors
Although sexual behavior may be accurately recalled, there may still be concerns regarding
correct condom use.37,40 Self-reports of condom use vary considerably in quality and level of
detail due to a lack of understanding of the term “use.”41 A couple may indeed have used a
condom but did not use it consistently or correctly, thereby negating its protective effects.
Typical condom-use errors include failure due to slippage, placing the condom on the penis
after initiation of sex, removing the condom before the end of the sexual episode, and placing
the incorrect side of the condom on the penis and needing to take it off, invert it, and re-place
it on the penis.42–45 In each of these cases, study participants may have recalled that they used
a condom, but attributable to condom-use errors, it may not be protective against STDs.
Research has shown that condom-use error is associated with increased STDs.44,46 In addition
to condom user errors, as described above, another problematic concern is condom failure or
the frequency of condom breakage. However, to minimize threats to internal validity, the trial
assessed the frequency of condom breakage and slippage for males and the ability of
participants to correctly apply condoms.
DEFINING THE PRIMARY BIOLOGICAL OUTCOME
The primary biological outcome is the proportion of participants (male study partners or female
study partners) with an incident STD (chlamydia, gonorrhea, and trichomoniasis) over the 12-
month postintervention follow-up period. The EBAN trial investigators sought to address
several factors that are crucial in using STDs as indicators of intervention efficacy. Specifically,
these factors included (1) choosing a quality referral laboratory, (2) selecting appropriate STDs
to comprise the primary outcome, (3) ensuring successful STD treatment at baseline, and (4)
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addressing components of STD transmission dynamics in the study design. These are discussed
below.
Choosing a Quality Referral Laboratory
To reduce the potential for variances in STD results and to meet the criteria of a quality referral
laboratory,47,49 the EBAN trial investigators decided to use a single laboratory, the Emory
University Department of Microbiology and Immunology laboratory, as the referral laboratory
for the STD testing and analysis. This laboratory functioned under a uniform set of organized,
comprehensive guidelines for diagnostic testing. A comprehensive manual outlining
standardized procedures for specimen collection, handling, preparation, shipment, testing, and
reporting was created for the trial and maintained by the laboratory staff and the trial
investigators. Additionally, quality assurance measures such as staff training, specimen
confirmatory testing, and inter-laboratory specimen testing were performed on a regular basis.
Selecting Appropriate STDs to Comprise the Primary Outcome
Including STDs as a primary outcome is more useful when the STDs are prevalent in the target
population. In the EBAN trial, STDs were selected that were among the most prevalent among
African American HIV-serodiscordant couples at each site and which could be easily treated
to ascertain incident infections acquired over the follow-up period. Scant research has
examined STD prevalence among HIV-serodiscordant couples in the United States. However,
prior research by EBAN trial investigators indicated that nearly 20% of African American
HIV-positive women had a prevalent infection with chlamydia, gonorrhea, or trichomonas.
28 Thus, in the EBAN trial, acquiring an incident nonviral STI was the primary outcome, this
outcome was defined as a laboratory-confirmed test for a new chlamydia, gonorrhea, or
trichomonas infection, at either the 6- or the 12-month follow-up assessment. Specimens for
Neisseria gonorrhoeae and Chlamydia trachomatis were assessed using the Becton Dickinson
ProbeTec ET Amplified DNA Assay (Becton, Dickinson and Company, Sparks, MD) and
Trichomonas vaginalis was assessed using Taq-Man polymerase chain reaction.50
Ensuring Successful STD Treatment of the Couple at Baseline
The goal of many HIV prevention trials that use STDs as their primary biological outcome is
to determine the efficacy of the intervention in reducing incident STDs.25 This is often
accomplished by testing participants at baseline for prevalent curable STDs (ie, chlamydia,
gonorrhea, or trichomoniasis) and treating participants who test positive for an STD.
Categorizing the participant as STD-negative at baseline is critical in HIV prevention trials as
it allows for STDs that are acquired during the follow-up period to be correctly classified as
incident STDs. Therefore, ensuring successful STD treatment at baseline is crucial. Participants
testing positive for an STD were treated with directly observable single oral dose therapy. If
one member of the couple tested positive for any of the study STDs assessed, the infected
partner was notified and scheduled for an appointment for treatment. Participants testing STD
positive received standard of care preventive counseling as per CDC guidelines regardless of
their HIV status. These practices were conducted to ensure that both members of the couple
were negative for the STDs assessed in the study at baseline.
Incorporating an Understanding of STD Transmission Dynamics in the Study Design
It is important to recognize at least 3 distinct components of STD transmission dynamics,
including the transmissibility of infection upon exposure between an infected and an uninfected
person, the likelihood of sexual exposure between infected and uninfected individuals, and the
duration of infection among infected individuals.5,51 This concept is highlighted in Anderson
and May’s equation Ro = βCD, where Ro is the rate of spread in a population, β is the
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transmission probability, C is the average contact rate, and D is the average duration of
infectiousness.
Consistent with this understanding of STD dynamics, the EBAN trial STD preventive
counseling and treatment procedures emphasized several points. First, the counseling
addressed the importance of reducing behaviors related to transmission of infection between
the HIV-infected and the uninfected partner, including abstaining from sex until the completion
of STD therapy. Additionally, given the importance of duration of infection or infectiousness,
having partners receive timely STD treatment was a priority for the trial. Conducting a couples-
level HIV intervention afforded the EBAN investigators a unique opportunity to provide timely
STD treatment to both members of the sexual dyad. This STD treatment strategy is not often
feasible in individual-level HIV interventions. Strategies aimed at enhancing partner STD
treatment are outlined in Table 2. These strategies were developed by a multidisciplinary team
composed of infectious disease physicians, infectious disease nurses, public health
professionals, and social science researchers from the 4 study sites.
Over the past few years, an increasing number of HIV prevention studies have addressed the
relationship between behavioral and biomedical outcomes of STD transmission. However, one
of the most novel aspects of the EBAN trial was the investigators’ ability to address these
critical issues of STD transmission dynamics among African American serodiscordant couples.
CONCLUSIONS
The EBAN trial is one of the largest randomized controlled trials of a behavioral intervention
to reduce the risk of HIV among African American serodiscordant couples. Among the
highlights of the assessment procedures developed for this study are the use of 2
complementary primary outcome measures (behavioral and biological) to assess trial efficacy.
Additionally, this trial employed multiple strategies to minimize potential threats to reliability
and validity of the primary behavioral outcome measure. Moreover, this trial employed
numerous strategies to minimize challenges in enhancing timely STD treatment in couples.
Behavioral outcomes provide useful data regarding the immediate target for the behavioral
intervention and are useful in low STD/HIV prevalence populations. However, there is not
always a high correspondence between engagement in risky sexual behaviors and acquisition
of incident STDs.7 Moreover, self-reported sexual behaviors are subject to numerous biases.
9–13 Conversely, biological outcomes provide a direct impact of the intervention on STD
incidence and can also provide important policy information for assessing the cost-
effectiveness of the intervention in preventing STDs among HIV-serodiscordant couples. The
trial investigators advocate the collection of both behavioral and biological end points when
assessing HIV intervention efficacy. Although this strategy may be more costly, timely, and
complex, it provides a more complete assessment of the impact of an intervention. However,
to reap the benefits of using behavioral and biological outcomes of HIV intervention efficacy,
procedures are required to address the limitations of each measure. EBAN trial investigators
sought to enhance the rigor of the study measures by developing such procedures and practices.
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Modes of Data Collection for the Primary Behavioral and Biological Outcome
Data Sources Purpose of DataCollection














































Timing of STD Treatment to Prevent STD Reinfection
Scenario Partner 1 Partner 2 Timing of STD Treatment toPrevent Reinfection
A Tests positivefor an STD
Tests positive for same STDs as partner 1
Treat partner 1 and partner 2
together at time 1Tests STD negative but requests
treatment
B Tests positivefor an STD
Tests negative for all STDs and reports
being sexually abstinent since initial STD
testing Treat partner 1 at time 1 andpartner 2 does not need
treatmentBoth partners self-report having protected
sex
C Tests positivefor an STD
Tests positive for same STDs as partner 1
and the partners do not present together
for treatment
Treat partner 1 at time 1 and
treat partner 2 within 24 hours
of partner 1; or treat both
partners together at time 2Tests STD negative but requests
treatment
D Tests positivefor an STD
Tests STD negative but requests STD
treatment
Treat partner 1 at time 1 and
partner 2 treated at time 2 (>24
hours after partner 1)
Reports being sexually abstinent since
initial STD testing
Both partners self-report having protected
sex
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